Corcept Therapeutics Inc. (NASDAQ:CORT) was up 2.1% on Monday . The stock traded as high as $5.96 and last traded at $5.95, with a volume of 145,731 shares. The stock had previously closed at $5.83.

Several equities research analysts have weighed in on CORT shares. Zacks Investment Research raised Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a report on Tuesday, July 12th. FBR & Co reissued an “outperform” rating and issued a $12.00 price target on shares of Corcept Therapeutics in a report on Thursday, June 23rd.

The company has a 50 day moving average price of $5.62 and a 200-day moving average price of $4.72. The stock’s market capitalization is $653.29 million.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, May 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.01. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $16.32 million. On average, analysts expect that Corcept Therapeutics Inc. will post $0.04 EPS for the current fiscal year.

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. acquired 100,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, May 10th. The stock was acquired at an average cost of $4.88 per share, for a total transaction of $488,000.00. Following the completion of the transaction, the director now owns 721,038 shares in the company, valued at approximately $3,518,665.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Corcept Therapeutics stock. Globeflex Capital L P boosted its position in Corcept Therapeutics Inc. (NASDAQ:CORT) by 164.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 244,301 shares of the company’s stock after buying an additional 151,869 shares during the period. Globeflex Capital L P owned approximately 0.22% of Corcept Therapeutics worth $1,217,000 as of its most recent SEC filing.

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.